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The percutaneous absorption of soman in a damaged skin porcine model 
and the evaluation of WoundStat™ as a topical decontaminant 
Purpose: The aim of this study was to evaluate a candidate haemostat (WoundStat™), 
down-selected from previous in vitro studies, for efficacy as a potential skin 
decontaminant against the chemical warfare agent pinacoyl methylfluorophosphonate 
(Soman, GD) using an in vivo pig model. 
Materials and methods: An area of approximately 3 cm2 was dermatomed from the 
dorsal ear skin to a nominal depth of 100 µm. A discrete droplet of 14C-GD (300 µg kg-
1) was applied directly onto the surface of the damaged skin at the centre of the dosing 
site. Animals assigned to the treatment group were given a 2 g application of 
WoundStat™ 30 s after GD challenge. The decontamination efficacy of WoundStat™ 
against GD was measured by the direct quantification of the distribution of 14C-GD, as 
well as routine determination of whole blood cholinesterase and physiological 
measurements. 
Results: WoundStat™ sequestered approximately 70% of the applied 14C-GD. Internal 
radiolabel recovery from treated animals was approximately 1% of the initially applied 
dose. Whole blood cholinesterase levels decreased to less than 10% of the original 
value by 15 minutes post WoundStat™ treatment and gradually decreased until the 
onset of apnoea or until euthanasia. All treated animals showed signs of GD 
intoxication that could be grouped into early (mastication, fasciculations and tremor), 
intermediate (miosis, salivation and nasal secretions) and late onset (lacrimation, body 
spasm and apnoea) effects. Two of the six WoundStat™ treated animals survived the 
study duration. 
Conclusions: The current study has shown that the use of WoundStat™ as a 
decontaminant on damaged pig ear skin was unable to fully protect against GD toxicity. 
Importantly, the findings indicate that the use of WoundStat™ in GD contaminated 
wounds would not exacerbate GD toxicity. These data suggest that absorbent 
haemostatic products may offer some limited functionality as wound decontaminants. 




Military personnel are constantly exposed to the risk of traumatic, penetrating injury on the 
battlefield (1-4) and various haemostatic treatments have been evaluated in combat settings 
(5-8). Should wounding occur in a chemically contaminated environment, such as after 
hostile deployment of a chemical warfare agent (CWA), the use of haemostatic treatments 
would be complicated by the need to decontaminate the wound site. Of major concern is 
whether the use of a haemostat on a chemically contaminated wound would increase systemic 
absorption. Rather than using separate strategies to arrest haemorrhage and decontaminate a 
wound site, the development of a product that simultaneously arrests haemorrhage and 
decontaminates wounds would have clear advantages. Studies involving the use of CWAs to 
evaluate the efficacy of potential medical countermeasures, by necessity, use animal models 
to indicate what would happen in humans. For studies involving the dermal exposure route, 
the pig is generally accepted as being the most representative model for man (9-10).  
Previous in vitro studies have demonstrated that haemostatic products may retain the 
ability to clot blood in the presence of CWAs and that certain products (based on absorptive 
powders) are able to effectively decontaminate CWAs from normal and superficially-
damaged skin (11-13).  One product, WoundStat™, was identified as being particularly 
effective in terms of its ability to decontaminate CWAs from undamaged or superficially-
damaged skin.  The purpose of the current study was to extend the evaluation of 
WoundStat™ to an in vivo, non-haemorrhaging wound model using the CWA soman 




The synthesis, use and destruction of soman (GD; pinacoyl methylfluorophosphonate) was 
conducted in accordance with the Chemical Weapons Convention (1996). Radiolabelled GD 
was synthesised by TNO (Rijswijk, Netherlands) and had a radiochemical purity >97% (as 
determined by radiometric HPLC analysis). The chemical purity of unlabelled GD (supplied 
by Dstl Detection Department, Salisbury, Wiltshire) was reported to be >97% (as measured 
by nuclear magnetic resonance spectroscopy). Radiolabelled and unlabelled GD were mixed 
in appropriate proportions to give a nominal activity of approximately 5 µCi µL-1. 
Isofluorane-VET® (isofluorane; Merial Animal Health Ltd, Essex, UK), Hypnovel® 
(midazolam hydrochloride (5 mg mL-1); Roche Products Ltd., Hertfordshire, UK), Dolethal® 
(sodium pentobarbitone (200 mg mL-1); Schering-Plough, Hertfordshire, UK) were purchased 
from a registered UK supplier. Medical grade oxygen and nitrous oxide were obtained from 
BOC Ltd. (Surrey, UK). Liquid scintillation counting (LSC) materials (Soluene-350, Ultima 
Gold and opaque plastic vials) were purchased from Perkin-Elmer (Chandler’s Ford, 
Hampshire). All other chemicals were analytical grade and were purchased from the Sigma 
Chemical Company (Poole, Dorset). 
Treatment 
The haemostat WoundStat™ was purchased from TraumaCure, Inc. (Bethesda, MD). 
Animal model 
The use of animals was in accordance with the Animals (Scientific Procedures) Act 1986. A 
total of 18 female weanling pigs (large white strain, weight range 15-25 kg) were purchased 
from a reputable supplier. Animals were given 24-h access to food and water. After a 
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minimum of one week’s acclimatisation, an individual animal was prepared for experiment 
according to the following protocol. 
Each animal was fasted overnight and then sedated with Hypnovel® (Midazolam, 
6mL i.m., 5 mg mL-1) prior to induction of gaseous anaesthesia (1.5-3% isofluorane delivered 
in 4-6 L min-1 O2 and 0.4-0.6 L min-1 N2O) via a nose cone. After the animal was fully 
anaesthetised, an endotracheal tube was inserted. Respiratory anaesthesia (as described 
above) was maintained via the endotracheal tube until completion of surgical preparation. To 
enable arterial and venous access, the internal carotid artery and jugular vein were 
cannulated. Upon completion of surgery, intravenous administration of Alfaxan 
(Alphaxalone, Astra Zeneca) commenced and 5 minutes later respiratory anaesthesia was 
discontinued. Alfaxan was delivered at a rate of 12 to 26 mL h-1 for the rest of the study. The 
general wellbeing of each animal was monitored continuously under anaesthesia using a 
Propaq vital signs monitor (Welch Allyn, Oregon USA). Parameters measured were arterial 
blood pressure, breathing rate, core temperature, CO2, ECG, pulse rate and SpO2. After a 30-
minute stabilisation period, the animal was placed into a sling. The animal and sling were 
moved carefully into a fume cupboard. The left ear of the animal was secured in a horizontal 
position, with the outer ear being made available for commencement of study procedures. 
Experimental procedures 
A total of 18 animals were used, with animals being assigned to either the treated (GD 
challenge, WoundStat™ treatment), control (no GD challenge, no WoundStat™ treatment) or 
untreated (GD challenge, no WoundStat™ treatment) group. An area of approximately 3 cm2 
was dermatomed (Humeca Model D42, Eurosurgical Ltd., Guildford, UK) from the dorsal ear 
skin to a nominal depth of 100 µm. Any transient bleeding that resulted from the procedure 
was removed with a saline-soaked cotton swab. A plastic dosing template was secured around 
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the edges of the dermatomed area using surgical glue (Vetbond™). Following a 30-minute 
baseline measurement period, a discrete droplet of 14C-GD (300 µg kg-1) was applied directly 
onto the surface of the damaged skin at the centre of the dosing template. Animals assigned 
to the treatment group were given a 2 g topical application of WoundStat™ directly to the 
exposure site 30 s after contamination with GD. Once placed, the WoundStat™ was left 
undisturbed for the duration of the study. Animals in the control (untreated) group were 
exposed to GD but not subject to the application of WoundStat™. Arterial blood samples 
were taken into both sodium EDTA tubes and sodium citrated tubes at regular intervals both 
pre and post GD challenge. Blood samples taken into sodium EDTA tubes were used for 
haematocrit quantification and analysis of whole blood cholinesterase activity. Blood samples 
taken into sodium citrate tubes were used for radiometric quantification. 
Terminal procedures 
Euthanasia was achieved by i.v. bolus of Dolethal® (sodium pentobarbitone; 6 mL, 200 mg 
mL-1) at 6 h (surviving animals) or 15 minutes after the onset of apnoea. The dosed ear was 
then carefully removed and the decontaminant (where appropriate) removed from the skin 
surface and placed in 16 mL of scintillation counting fluid (Ultima Gold, PerkinElmer LAS 
(UK) Ltd., Buckinghamshire, UK). The dosing template was removed and placed in 20 mL 
isopropanol. The skin surface was swabbed with cotton wool (to remove any residual GD) 
and the swab was placed in 16 mL of isopropanol. The skin exposure site was excised, and 
the periphery and the central area of the dosing site were separated to enable determination of 
skin surface spread from the central dosing area. These skin samples were placed in 16 mL 
Soluene-350. Each animal was then exsanguinated prior to post-mortem examination. Major 
organs (brain, heart, kidney, liver, lung, pancreas and spleen) were removed, weighed and 
frozen for subsequent radiometric analysis. 
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Whole blood cholinesterase measurement 
A modified Ellman assay (14) was used to quantify whole blood cholinesterase. Briefly, 
enzyme activity was measured via reaction of thiocholine with 5,5-dithiobis-(2 nitrobenzoic) 
acid (DTNB). Prior to analysis, samples of arterial whole blood had been stored at -20°C for 
at least a week in sodium EDTA tubes. A 25 µL sample of whole blood was made up to 5 mL 
in a pH 8.0 phosphate buffer. A 1 mL sample of the resulting blood solution was incubated at 
30°C in a cuvette containing both acetylthiocholine iodide (1 mM) and DTNB (0.25 mM). 
The reaction, monitored at 412 nm, was measured over a 10-minute period using a Biochrom 
Ultrospec 6300 spectrophotometer. Appropriate blanks (substrate and tissue) were run 
simultaneously with the test samples and were subtracted from the test reaction. 
Radiometric analysis 
Vials containing the dosing chamber, skin surface swab, dissolved skin were stored at room 
temperature (with occasional shaking) for up to two weeks, after which aliquots (250 µL) 
were removed into 5 mL of scintillation fluid. Organ samples (approximately 0.1 g) were 
dissected in triplicate, placed into 2 mL Soluene within a glass scintillation vial and heated at 
60ºC for a period of 4 hours. After cooling to room temperature, 20 mL of Ultima gold liquid 
scintillation fluid was added to each vial. The method described by Moore (15) was used for 
blood sample preparation, as follows: a blood sample (0.4 mL) was placed into a glass liquid 
scintillation vial. To this 1 mL of a Soluene and isopropanol (1:2 ratio) mixture was added 
whilst the vial was swirled gently. Each vial was then heated at 60ºC for 2 hours. After 
cooling, 0.5 mL of 30% hydrogen peroxide was added with gentle agitation until foaming had 
subsided. Vials were allowed to stand for a period of 30 minutes prior to being heated to 60ºC 
for a period of 30 minutes. After cooling for 15 minutes, 15 mL of Ultima gold liquid 
scintillation fluid was added to each vial. The amount of radioactivity in each sample was 
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measured using a PerkinElmer Tri-Carb liquid scintillation counter (Model 2810 TR), with 
the manufacturer’s 14C-quench curve library set to exclude single-photon (non-radioactive) 
events. The amount of radioactivity in each sample was converted to an amount of GD by 
comparison to standards (containing known quantities of 14C-GD) prepared and measured 
simultaneously. The total amount of GD contained within each organ was calculated by 
reference to the total weight of the organ weighed at post mortem. The total amount of GD in 
the circulating blood volume was derived from the analysis of Bush (16), where the Total 
Blood Volume = (161.48 × total animal weight -0.297) × total animal weight / 1000. 
Absorption of 14C-GD was measured according to the appearance of radiolabel within the 
circulating blood volume at defined time points after 14C-GD challenge to the dosing site. 
Radiometric analyses were grouped as external quantification, local quantification and 
internal quantification. External quantification grouped the unabsorbed fraction of GD and 
included the portions of radioactivity remaining on the skin surface or sequestered into the 
WoundStat™ treatment. Local quantification grouped radioactivity recovery within the skin 
at the dosing site and at the periphery of the dosing site. Internal quantification grouped the 
portions of radioactivity located in the blood, liver, kidney, pancreas, spleen, heart, lung and 
brain. Any radioactivity unaccounted for was assumed to have either volatilised from the skin 
surface or to have been present in unsampled organs. 
Statistical analysis 
GraphPad Prism version 6.01 for Windows (GraphPad Software) was used for normality 
testing, statistical analysis and graphical presentation of the data. Data were assessed for 
normal distribution using a D’Agostino and Pearson omnibus normality test and a Gaussian 
non-linear regression curve fit. Significance was predefined at an alpha-level of 0.05. 
Survival fractions and survival curve were analysed using the Kaplan-Meier (log-rank) 
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method, and Gehan–Brislow–Wilcoxon tests. Comparisons across multiple experimental 
groups were performed using a non-parametric ANOVA (Kruskal–Wallis test) with Dunn’s 
multiple comparisons post-test or a Mann–Whitney test (comparison of pre-exposure and 
final measurements within the same experimental group). 
Results 
Survival and gross clinical observations 
Application of GD to damaged skin in vivo resulted in the rapid onset of multiple observable 
(Table 1) or physiological (Table 2) signs of nerve agent poisoning. In addition, only one of 
the animals in the GD-exposed untreated group survived to six hours post-exposure (Figure 
1) and median survival time differed significantly between the control and GD-exposed 
untreated groups (Figure 2). Two animals in the GD-exposed WoundStat™-treated group 
survived until the end of the study period (Figure 1). Signs of nerve agent poisoning were 
also observed in these animals, although there tended to be a longer latency in the onset of 
signs when compared to the untreated group (Table 1). In addition, there was no significant 
difference in median survival time between the GD-exposed WoundStat™-treated group and 
the unexposed control group (Figure 2). All six animals in the control group survived the six-
hour study duration and showed no sign of GD intoxication.  
Toxicodynamics 
The clinical signs observed in the GD-exposed untreated group were accompanied by a rapid 
depression of whole blood cholinesterase to less than 5% of baseline values by 15 minutes 
post exposure (Figure 3) and an increase in whole blood haematocrit (Figure 4). Similarly, 
the GD-exposed WoundStat™-treated group exhibited rapidly decreasing whole blood 
cholinesterase (Figure 3) and increased haematocrit (Figure 4) during the study. 
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Toxicokinetics 
Blood levels of 14C-GD reached a maximum within 10 minutes of GD challenge for both 
untreated and WoundStat™ treated groups (Figure 5). In the WoundStat™ treatment group, 
the amount of 14C-GD in the blood had halved by 20 minutes post-exposure and remained 
constant at this level for the study duration. In contrast, in the untreated group, the amount of 
14C-GD in the blood steadily increased as the study progressed. Comparison of whole blood 
cholinesterase and the amount of 14C-GD in the blood indicated that a blood recovery of >15 
µg 14C-GD resulted in maximum cholinesterase inhibition (Figure 6). 
Distribution 
Upon completion of the untreated studies, the majority of the applied 14C-GD was located 
either on the skin surface or within the skin at the dosing site, while a smaller portion of 
radioactivity was recovered from the periphery of the dosing site (Figure 7a-d). In 
comparison, for the treated animals the majority (approximately 70%) of the applied 14C-GD 
was sequestered by Woundstat™ (Figure 7a-d). The quantity of 14C-GD internalised in 
organs was approximately 1.75% or 1% of the initially applied 14C-GD for the untreated and 
Woundstat™ treated animals, respectively (Figure 8). 
Discussion 
The in vivo studies reported here used terminally anaesthetised large white pigs, with the GD 
challenge applied to the ear of the animal. This model and dosing site has been used 
previously for the assessment of countermeasures against nerve agents (17,18). In contrast to 
the previous studies, this is, to the authors’ knowledge, the first time that the skin had been 
damaged to allow a more rapid ingress of chemical warfare agent, in order to model a non-
haemorrhaging, contaminated wound. 
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The current study has shown that the use of WoundStat™ as a decontaminant on 
damaged (non-haemorrhaging) pig ear skin was unable to protect against GD toxicity. Most 
importantly, however, the use of WoundStat™ did not enhance the toxicity of GD. 
WoundStat™ decontamination 30 seconds post GD challenge sequestered 68% ± 
26% of the 14C-GD applied. Contemporary studies evaluating WoundStat™ as a 
decontaminant against the vesicating agent sulphur mustard gave increased recoveries of 99% 
± 8% (19). Given that similar experimental procedures were used, it is likely that the 
differences in recovery are ascribable to differences in physicochemical properties, such as 
volatility, between the two CWAs. In the case of GD, it is likely that a proportion volatilised 
or was absorbed prior to decontaminant application and was therefore not available for 
absorption by WoundStat™. Similar levels of WoundStat™ 14C-GD decontamination were 
measured during in vitro studies for both damaged and undamaged skin (20), indicating that 
decontamination should be carried out as rapidly as possible to limit the percutaneous 
absorption of GD. 
Decontamination with WoundStat™ substantially reduced the amount of 14C-GD 
remaining on the skin surface (1.8% ± 1.9% versus 16.7% ± 20.8% for treated and untreated 
animals, respectively) and within the skin (7.5% ± 3.8% versus 42.7% ± 22.7%). The 14C-GD 
remaining on or within the skin would not have impacted upon the observed and measured 
systemic toxicity. The systemic toxicity can be attributed to the internally absorbed dose of 
GD. WoundStat™ treatment resulted in a reduction of internally measured 14C-GD by 
approximately 0.5% (1.2% ± 0.3%versus 1.7% ± 0.6%). This equated to a 30% reduction in 
systemically recovered material.  
Despite this substantial reduction, whole blood cholinesterase measurements and 14C-
GD blood levels were similar whether or not WoundStat™ decontamination had been carried 
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out. Both experimental groups had animals that had high initial levels of 14C-GD in the blood, 
associated with rapidly declining whole blood cholinesterase. These animals did not survive 
for more than 45 minutes into the exposure period. In the WoundStat™ decontaminated 
animals that survived the initial period, 14C-GD blood levels and whole blood cholinesterase 
levels stabilised by 30 minutes and remained constant for the study duration. Conversely, for 
those animals in the untreated group that survived the initial period, cholinesterase levels 
remained below 5% of baseline values, whereas 14C-GD blood levels increased steadily until 
death or study termination. For both the untreated and the WoundStat™ decontaminated 
animals, haematocrit levels increased steadily over the exposure duration, whereas for the 
control group haematocrit levels were consistently lower and remained constant. Importantly, 
although WoundStat™ was not an effective decontaminant against GD, it did not exacerbate 
GD toxicity. One of the major concerns regarding the treatment of GD-contaminated wounds 
was whether the use of a haemostat would increase the systemic absorption of GD. The 
current study found that WoundStat™ had no such effect. 
In the current study, WoundStat™ was evaluated as a decontaminant in the absence of 
additional medical countermeasures. Should nerve agent exposure be confirmed, then further 
specific medical countermeasures would be employed alongside decontamination. The 
benefit of using decontaminants to increase survival times, allowing longer therapeutic 
windows for specific medical countermeasures to be employed, has been described 
previously (21).  
Conclusion 
The current study has shown that use of the haemostat WoundStat™, as a decontaminant for 
the nerve agent GD, was unable to protect against the effects of GD toxicity. Importantly, 
however, the findings of this study indicate that the use of WoundStat™ in GD-contaminated 
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wounds does not exacerbate GD toxicity. 
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 Table 1. Observed signs of GD poisoning in the anaesthetised large white pig for the three 
experimental groups: Control (no GD, no treatment); Untreated (GD, no treatment); Treated 
(GD with WoundStat™ treatment 30 seconds post GD application). Each group contained 6 
animals. ‘Frequency’ is the number of animals in the group that displayed the observable 
sign, with either the time to onset of the sign or the amount of saliva produced. Values are 
mean ± standard deviation calculated from the animals that responded.         
 
  Control Untreated Treated 
Miosis 
Frequency 0 2* 4* 
Time to onset (min) N/A 25 ± 18 71 ± 126 
Mastication 
Frequency 1 4 3 
Time to onset (min) 42 6 ± 1 7 ± 3 
Fasciculation 
(head/face/neck) 
Frequency 0 6 5 
Time to onset (min) N/A 7 ± 9 11 ± 12 
Fasciculation (limbs 
and rest of body) 
Frequency 1 3 1 
Time to onset (min) 21 6 ± 1 13 
Tremor / 
Convulsion 
Frequency 0 3 0 
Time to onset (min) N/A 33 ± 38 N/A 
Hypersalivation 
Frequency 1 5 4 
Amount (g) 3.84 19.4 ± 19.9 22.6 ± 18.4 
Apnoea 
Frequency 0 6† 4 
Time to onset (min) N/A 80 ± 101 127 ± 153 
*The incidence of miosis was lower in the untreated animals because 4 of them died too 
quickly for the observation/development of miosis. 
†The animal in the untreated group that survived experienced a transient episode of apnoea. 
 Table 2. Monitored physiological signs in pigs during steady state anaesthesia both pre GD 
exposure and at the end of the study (immediately preceding apnoea or euthanasia) for the 
three experimental groups: Control (no GD, no treatment); Untreated (GD, no treatment); 
Treated (GD with WoundStat™ treatment 30 seconds post GD application). Values are mean 
± standard deviation of n=6 animals. *Significant difference (p<0.05) between Pre-exposure 
and End values. 
 
  Control Untreated Treated 
Pulse rate 
Pre-exposure 163 ± 19 163 ± 30 146 ± 34 
End 156 ± 31 115 ± 71 130 ± 24 
Systolic pressure (mmHg) 
Pre-exposure 120 ± 9 113 ± 7 122 ± 18 
End 106 ± 10 88 ± 36 108 ± 40 
Diastolic pressure (mmHg) 
Pre-exposure 93 ± 7 84 ± 7 93 ± 15 
End 79 ± 9 51 ± 36 70 ± 38 
Mean pressure (mmHg) 
Pre-exposure 107 ± 6* 99 ± 6 109 ± 18 
End 93 ± 8* 65 ± 38 87 ± 39 
CO2 (kPa) 
Pre-exposure 6.2 ± 0.1 6.7 ± 0.6 7.2 ± 1.0 
End 5.9 ± 0.7 4.6 ± 3.7 7.5 ± 3.7 
Breathing rate (min-1) 
Pre-exposure 36 ± 13 29 ± 9* 33 ± 13* 
End 33 ± 9 6 ± 5* 17 ± 12* 
SpO2 (%) 
Pre exposure 93 ± 3 91 ± 7* 88 ± 5 
End 92 ± 7 46 ± 40* 61 ± 36 




38.2 ± 0.6 
38.1 ± 0.5 
36.5 ± 2.2 
36.6 ± 1.5 
36.7 ± 0.8* 
34.4 ± 2.2* 
  
 Figure legends 
 
Figure 1. Survival curve for anaesthetised swine exposed to a multiple LD50 (300 µg kg-1) 
dose of neat 14C-GD via damaged ear skin (untreated; n=6); similarly exposed swine treated 
with the test decontaminant, WoundStat™ (treated; n=6); and anaesthetised unexposed 
animals (control; n=6).   
 
Figure 2. Survival times for anaesthetised swine exposed to a multiple LD50 (300 µg kg-1) 
dose of neat 14C-GD via damaged ear skin (untreated; n=6); similarly exposed swine treated 
with the test decontaminant, WoundStat™ (treated; n=6); and anaesthetised unexposed 
animals (control; n=6). Individual data points are plotted and the central line represents the 
median value. The asterisk indicates a significant difference in survival time compared to the 
control group (capped bar; *p<0.05). 
 
Figure 3. Total whole blood cholinesterase (ChE), shown as a percentage of the original (pre 
GD challenge) activity in anaesthetised pigs following damaged ear exposure to liquid GD. 
All values are mean ± standard deviation of up to 6 animals. All groups comprised 6 animals, 
with the untreated and treated animals receiving a 0.3 mg kg-1 GD challenge on to damaged 
ear skin. The treated animal group received WoundStat™ treatment at 30 seconds post GD 
contamination. The control group were not exposed to GD and did not receive treatment. 
 
Figure 4. Total whole blood haematocrit (%) in anaesthetised pigs pre and post exposure to 
liquid GD on damaged ear skin. Pre exposure values were taken immediately prior to GD 
exposure, whilst the post exposure values were taken either immediately prior to the animal 
succumbing to GD toxicity, or upon completion of the 6 hour study duration. The treated 
animal group received WoundStat™ treatment at 30 seconds post GD contamination. The 
control group were not exposed to GD and did not receive treatment. All values are mean ± 
standard deviation of 6 animals. *Significant difference (p<0.05) between Pre- and Post-
exposure values. 
  
Figure 5. Amount of 14C-GD present in the blood of large white pigs after GD application on 
to damaged ear skin for untreated and WoundStat™-treated animals. One animal in the 
untreated group and two animals in the treated group survived for the maximum study 
duration of 6 hours. Those animals with larger amounts of 14C-GD present in the blood earlier 
in the time course succumbed to the toxic effects of GD within 45 minutes of challenge. Each 
animal received a GD dose at t=0 of 0.3 mg kg-1. All pre GD challenge values are mean ± 
standard deviation of n=6 animals, which decreased as animals succumbed to GD toxicity 
over the study duration. 
 
Figure 6. Comparison of whole blood cholinesterase (% of original) and the amount of 14C-
GD (or breakdown products) in the blood (determined from quantification of radiolabel) for 
untreated and WoundStat™-treated animals. Each animal received a GD dose of 0.3 mg kg-1 
on to damaged ear skin. A least-squares fit non-linear regression analysis was used to curve 
fit the data for each group. The equations for the curves were: Untreated Y= (92.22-
1.484)*exp(-0.2739X) + 1.484 and Treated Y= (95.42-3.604)*exp(-0.1930X) + 3.604. 
 
Figure 7. 14C-GD distribution for WoundStat™-treated and untreated animals after a 0.3 mg 
kg-1 damaged ear skin exposure, expressed as a percentage of the applied dose.  
A. Total Recovery. Sampled compartments were: WoundStat™-sequestered (treated animals 
only), GD remaining on damaged skin surface, GD present with the skin directly under the 
dosing site, GD present within the skin adjacent to the dosing site, GD absorbed into the 
dosing assembly and GD recovered from sampled organs (detailed in Figure 6). 
Compartments were sampled either after the animal had succumbed to GD toxicity or upon 
completion of the 6 hour study duration.  
B. External Quantification. Compartments shown: WoundStat™-sequestered (treated animals 
only), GD remaining on damaged skin surface and GD absorbed into the dosing assembly. 
C. Local Quantification. Compartments shown: GD present with the skin directly under the 
dosing site and GD present within the skin adjacent to the dosing site. 
 D. Internal Quantification. Compartment shown: GD recovered from sampled organs 
(detailed in Figure 6). 
All values are mean ± standard deviation of n=6 animals. *†Statistically significant (p<0.05) 
differences in the respective parameters between the Treated and Untreated groups. 
 
Figure 8. 14C-GD internal organ distribution for WoundStat™-treated and untreated animals 
after a 0.3 mg kg-1 damaged ear skin exposure, expressed as a percentage of the applied dose. 
Sampled internal organs were heart, spleen, lung, pancreas, liver, kidney, blood and brain. 
Organs were harvested after either the animal had succumbed to GD toxicity or upon 
completion of the 6 hour study duration. Recovery from within the systemic circulation was 
determined from the final blood sample taken prior to the end of each study. All values are 
mean ± standard deviation of n=6 animals. *Statistically  significant (p<0.05) difference 
between the Treated and Untreated groups. 
 
